Compare ETD & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETD | OVID |
|---|---|---|
| Founded | 1932 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 562.5M |
| IPO Year | 1996 | 2017 |
| Metric | ETD | OVID |
|---|---|---|
| Price | $21.29 | $2.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $27.00 | $4.60 |
| AVG Volume (30 Days) | 597.0K | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 8.15% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ 1.56 | N/A |
| Revenue | ★ $766,784,000.00 | $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.73 | $19.34 |
| P/E Ratio | $13.49 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $18.28 | $1.18 |
| 52 Week High | $29.61 | $3.11 |
| Indicator | ETD | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 36.83 |
| Support Level | $21.11 | $2.38 |
| Resistance Level | $22.95 | $2.77 |
| Average True Range (ATR) | 0.51 | 0.12 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 36.46 | 11.36 |
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.